IBRX (STOCKS)
ImmunityBio, Inc. Common Stock
$7.650000
-0.090000 (-1.16%)
Prev close: $7.740000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Richard Adcock
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $8,788.25M
- Employees
- 685
- P/E (TTM)
- -7.99
- P/B (TTM)
- -7.79
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
4
Strong Buy
5
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Jun 2026 (Q2)
|
$-0.22 | $-0.09 | -0.1282 | -139.65% |
|
Mar 2026 (Q1)
|
$-0.08 | $-0.07 | -0.0086 | -12.04% |
|
Dec 2025 (Q4)
|
$-0.06 | $-0.10 | +0.0359 | +37.43% |
|
Sep 2025 (Q3)
|
$-0.07 | $-0.11 | +0.0402 | +36.48% |
Financial Statements
| Revenues | $165.79M |
| Benefits Costs and Expenses | $1.16B |
| Cost Of Revenue | $1.10M |
| Costs And Expenses | $417.59M |
| Gross Profit | $164.70M |
| Nonoperating Income/Loss | -$740.78M |
| Operating Expenses | $416.50M |
| Operating Income/Loss | -$251.80M |
| Income/Loss From Continuing Operations After Tax | -$992.42M |
| Income/Loss From Continuing Operations Before Tax | -$992.58M |
| Income Tax Expense/Benefit | -$161.00K |
| Net Income/Loss | -$992.42M |
| Net Income/Loss Attributable To Noncontrolling Interest | -$62.00K |
| Net Income/Loss Attributable To Parent | -$992.36M |
| Net Income/Loss Available To Common Stockholders, Basic | -$992.36M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$0.97 |
| Diluted Earnings Per Share | -$0.97 |
| Basic Average Shares | 3,047,073,000 |
| Diluted Average Shares | 3,047,073,000 |
| Assets | $628.50M |
| Current Assets | $438.98M |
| Inventory | $1.94M |
| Other Current Assets | $437.04M |
| Noncurrent Assets | $189.52M |
| Fixed Assets | $114.22M |
| Other Non-current Assets | $75.30M |
| Liabilities | $1.67B |
| Current Liabilities | $76.73M |
| Noncurrent Liabilities | $1.60B |
| Equity | -$1.05B |
| Equity Attributable To Noncontrolling Interest | $868.00K |
| Equity Attributable To Parent | -$1.05B |
| Liabilities And Equity | $628.50M |
| Net Cash Flow From Operating Activities | -$281.14M |
| Net Cash Flow From Operating Activities, Continuing | -$281.14M |
| Net Cash Flow From Investing Activities | -$276.91M |
| Net Cash Flow From Investing Activities, Continuing | -$276.91M |
| Net Cash Flow From Financing Activities | $496.78M |
| Net Cash Flow From Financing Activities, Continuing | $496.78M |
| Net Cash Flow | -$61.26M |
| Net Cash Flow, Continuing | -$61.26M |
| Comprehensive Income/Loss | -$977.70M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | -$62.00K |
| Comprehensive Income/Loss Attributable To Parent | -$977.64M |
| Other Comprehensive Income/Loss | $14.72M |